With over three decades of experience, Dr Gunn has held pivotal roles in leading biotech firms and academic institutions including Pfizer, Crucell (Johnson & Johnson), Becton Dickson, Clintec (IQVIA), ICON, and Health Decisions (Premier Research). She is a corporate strategy expert with extensive experience in life science corporate development, strategic partnerships, co-development, licensing partnerships, M&A and post-merger integrations. She is renowned for her extensive contributions to medical research, innovative drug development, contract research and clinical trials, and has spearheaded the development of several FDA-approved drugs, particularly in the CNS and vaccines domains. She is passionate about market access to innovation.
